SCHEMBL2728906

SCHEMBL2728906

Cc1cc([N+](=O)[O-])ncc1CC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
AGBL2 Q5U5Z8 2/20 0.40
ALOX15 P16050 1/20 0.39
HTT P42858 1/20 0.38
SRC P12931 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXRA P19793 2/20 0.35
RXRB P28702 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
RXRG P48443 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
AMY1A P0DUB6 1/20 0.34
TSHR P16473 2/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2728907 1.00 CYP1A2 (0.42) CYP1A2AGBL2ALOX15HTTSRC
SCHEMBL2729044 0.73 NOS3 (0.65) AGBL2ALOX15SRCNPSR1RXRA
SCHEMBL2728190 0.73 ALDH1A1 (0.38) HTTKMT2APOLBTSHRALDH1A1
SCHEMBL2728187 0.73 ALDH1A1 (0.38) HTTKMT2APOLBTSHRALDH1A1
SCHEMBL2728192 0.73 MITF (0.35) HTTMEN1KMT2ALMNAPOLB
SCHEMBL16641779 0.72 CYP1A2 (0.53) CYP1A2ALOX15NPSR1RXRARXRB
SCHEMBL16527056 0.72 CYP1A2 (0.53) CYP1A2ALOX15NPSR1MEN1KMT2A
SCHEMBL11619323 0.71 NNMT (0.53) HTTNPSR1KMT2ALMNAPOLB
SCHEMBL9323520 0.71 CYP1A2 (0.69) CYP1A2RXRARXRBMEN1KMT2A
SCHEMBL1625912 0.71 CYP1A2 (0.69) CYP1A2RXRARXRBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2790511-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2016-09-14 EP disclosed
US-9206199-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2015-12-08 US disclosed
US-9056859-B2 Inhibitors of the renal outer medullary potassium channel MERCK SHARP & DOHME CORP. (US) 2015-06-16 US disclosed
EP-2632464-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2015-04-29 EP disclosed
US-20140336177-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC 2014-11-13 US disclosed
EP-2790511-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL Merck Sharp & Dohme Corp. (US) 2014-10-22 EP disclosed
EP-2632464-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL Merck Sharp & Dohme Corp. (US) 2013-09-04 EP disclosed
US-20130217680-A1 Inhibitors of the Renal Outer Medullary Potassium Channel MERCK SHARP & DOHME LLC 2013-08-22 US disclosed
WO-2013090271-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2013-06-20 WO disclosed
WO-2012058134-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2012-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217680-A1 Inhibitors of the Renal Outer Medullary Potassium Channel KCNJ11, KCNJ1, KCNJ2 CYP1A2 3208/4885AGBL2 4735/4885ALOX15 3050/4885
US-20140336177-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ11, KCNJ1, KCNJ2 CYP1A2 3522/4885AGBL2 4667/4885ALOX15 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.